Active Stocks
Thu Mar 28 2024 15:59:33
  1. Tata Steel share price
  2. 155.90 2.00%
  1. ICICI Bank share price
  2. 1,095.75 1.08%
  1. HDFC Bank share price
  2. 1,448.20 0.52%
  1. ITC share price
  2. 428.55 0.13%
  1. Power Grid Corporation Of India share price
  2. 277.05 2.21%
Business News/ Companies / Company-results/  Cipla Q1 net profit up 120% to Rs651 crore
BackBack

Cipla Q1 net profit up 120% to Rs651 crore

Profit increased from Rs295 crore in the same period last year on strong growth in formulation exports

Exports of formulations increased 78.5% to Rs2,174 crore during the three months ended June, from Rs1,218 crore a year ago. Premium
Exports of formulations increased 78.5% to Rs2,174 crore during the three months ended June, from Rs1,218 crore a year ago.

Mumbai: Cipla Ltd posted a consolidated net profit of 651 crore for the quarter ended 30 June, against 295 crore in the same period last year, on strong growth in formulation exports.

Total income increased to 3,852 crore from 2,720 crore a year ago.

Exports of formulations increased 78.5% to 2,174 crore during the three months ended June, from 1,218 crore a year ago. Exports of active pharmaceutical ingredients (APIs) increased by 47% to 206 crore.

Domestic sales in the June quarter grew 8.4% to 1,397 crore, from 1,289 crore in the year-ago period, on account of increased sales in respiratory, anti-infective, cardiac and gastro-intestinal categories, stated a press release. Material cost for the June quarter came in at 32.5% of income from operations, against 37.7% a year ago.

The group posted a net profit of 1,181 crore for the year ended 31 March, against 1,388 crore in 2013-14. Total income increased from 10,439 crore in 2013-14 to 11,511 crore in 2014-15.

On Friday, shares of Cipla went up 2.06% to 740.50 on BSE, while the benchmark Sensex gained 1.88% to close at 28,067.31 points.

Last month, Cipla had received investment from FIL Capital Investments Mauritius II Ltd, the investment arm of Fidelity Growth Partners India, in its newly formed consumer healthcare subsidiary.

Through Cipla Consumer Healthcare, the company has re-entered the fast-growing over-the-counter (OTC) healthcare market in India. In 2010, Cipla exited the OTC market by selling its emergency contraceptive brand i-Pill to Piramal Healthcare Ltd for 95 crore.

The Cipla board had approved the divestment of its consumer healthcare business to a wholly owned subsidiary for a consideration of 10.5 crore. Cipla’s consumer healthcare division recently launched its first product Nicotex, a gum used to help smokers quit.

The consumer healthcare division reported sales of 34.88 crore, or about 0.3% of total revenue, in the year ended 31 March.

Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

Catch all the Corporate news and Updates on Live Mint. Download The Mint News App to get Daily Market Updates & Live Business News.
More Less
Published: 14 Aug 2015, 07:46 PM IST
Next Story footLogo
Recommended For You
Switch to the Mint app for fast and personalized news - Get App

Chat with MintGenie